Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8995937 | 0.93 | TGM2 (0.59) | TGM2ALDH1A1PKMMEN1KMT2A | |
| SCHEMBL732934 | 0.86 | TGM2 (0.81) | TGM2ALDH1A1MEN1KMT2A | |
| SCHEMBL15338482 | 0.85 | ALDH1A1 (0.59) | ALDH1A1PKMMEN1KMT2ACYP3A4 | |
| SCHEMBL8478088 | 0.84 | ALDH1A1 (0.69) | TGM2ALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL8476285 | 0.84 | MEN1 (0.60) | TGM2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL23542540 | 0.83 | ALDH1A1 (0.57) | ALDH1A1PKMMEN1KMT2ACYP3A4 | |
| SCHEMBL11927835 | 0.83 | TGM2 (0.63) | TGM2ALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL25791108 | 0.82 | MEN1 (0.61) | ALDH1A1PKMMEN1KMT2ACYP3A4 | |
| SCHEMBL25791110 | 0.82 | MEN1 (0.61) | ALDH1A1PKMMEN1KMT2ACYP3A4 | |
| SCHEMBL529067 | 0.82 | TGM2 (0.61) | TGM2ALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146122-A1 | POLYMERS | MOLECULAR MEDICAL LTD (GB) | 2026-05-28 | — | — | US | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4594380-A1 | POLYMERS | Molecular Medical Ltd (GB) | 2025-08-06 | — | — | EP | disclosed |
| US-20250206750-A1 | NOVEL METHOD FOR PRODUCING RUCAPARIB THAT IS PARP INHIBITOR AND INTERMEDIATE THEREOF | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-06-26 | — | — | US | disclosed |
| US-20250121069-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4491236-A2 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| EP-3454856-B1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12076405-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. | 2024-09-03 | — | — | US | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-0478268-A1 | Polymerizable substituted amide compound, polymer obtained therefrom and nonlinear optical material using the same | Nippon Paint Co., Ltd. (JP) | 1992-04-01 | — | — | EP | disclosed |
| EP-0272208-B1 | AROMATICALLY SUBSTITUTED AZACYCLO-ALKYLALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1991-06-12 | — | — | EP | disclosed |
| EP-0166692-B1 | SUBSTITUTED AZABICYCLOHEPTANES, THEIR USE, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESS FOR THE PREPARATION OF THE COMPOUNDS | CIBA-GEIGY AG (CH) | 1990-07-11 | — | — | EP | disclosed |
| US-4871720-A | Aromatically substituted azacycloalkyl-alkanediphosphonic acids useful for the treatment of illnesses that can be attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| US-4857660-A | ENZYME INHIBITORS, ANTICANCER AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-08-15 | — | — | US | disclosed |
| US-4764640-A | AROMATOSE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1988-08-16 | — | — | US | disclosed |
| EP-0272208-A1 | Aromatically substituted azacyclo-alkylalkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
| US-4677129-A | Substituted-3-azabicyclo[3.1.1]heptane-2,4-diones useful for treating hormone-dependent diseases | CIBA-GEIGY CORPORATION (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0166692-A2 | Substituted azabicycloheptanes, their use, pharmaceutical compositions comprising them and process for the preparation of the compounds | CIBA-GEIGY AG (CH) | 1986-01-02 | — | — | EP | disclosed |
| US-3936307-A | Light and heat sensitive composition for producing a colored transfer complex image | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JA) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | TGM2 1751/4885ALDH1A1 3454/4885PKM 4632/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | TGM2 418/4885ALDH1A1 2819/4885PKM 3354/4885 |
| US-12076405-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | TGM2 2834/4885ALDH1A1 4029/4885PKM 3699/4885 |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | TGM2 418/4885ALDH1A1 2819/4885PKM 3354/4885 |
| US-20250121069-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | TGM2 2834/4885ALDH1A1 4029/4885PKM 3699/4885 |
| US-20260146122-A1 | POLYMERS | FGB, IPMK, PFKP | TGM2 3308/4885ALDH1A1 1061/4885PKM 8/4885 |
| US-20250206750-A1 | NOVEL METHOD FOR PRODUCING RUCAPARIB THAT IS PARP INHIBITOR AND INTERMEDIATE THEREOF | PARP1, PARP3, PARP2 | TGM2 4077/4885ALDH1A1 1367/4885PKM 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.